Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Nephros, Inc.✕ NEPH · #22,480 in the world | Alcon Inc.✕ ALC · #705 in the world |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇨🇭 Switzerland |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments | Medical Instruments |
| Founded | — | 1945 |
| Size | ||
| Market cap | $36 M | |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Nephros, Inc. | Alcon Inc. |
|---|---|---|
| 2025 | $19 MSEC | $10.4 BSEC |
| 2024 | $14 MSEC | $9.9 BSEC |
| 2023 | $14 MSEC | $9.5 BSEC |
| 2022 | $10 MSEC | $8.7 BSEC |
| 2021 | $10 MSEC | $8.3 BSEC |
| 2020 | $9 MSEC | $6.8 BSEC |
| 2019 | $10 MSEC | $7.5 BSEC |
| 2018 | $6 MSEC | $7.2 BSEC |
| 2017 | $4 MSEC | $6.8 BSEC |
| 2016 | $2 MSEC | — |
| 2015 | $2 MSEC | — |
| 2014 | $2 MSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $37.1 B |
| Revenue | $19 M | $10.4 B |
|---|
| Net income | $1 M | $980 M▲ best |
|---|
| Employees | 36 | 25,000 |
|---|
| Valuation | ||
|---|---|---|
| P/E ratio | 18.7× | 37.9× |
| Price to sales | 1.6× | 3.6× |
| Price to book | 3.5× | 1.7× |
| Free cash flow yield | -1.6% | 4.7%▲ best |
| Profitability | ||
|---|---|---|
| Gross margin | 61.8%▲ best | 55.2% |
| Operating margin | 6.1% | 13.1%▲ best |
| Net margin | 6.3% | 9.4%▲ best |
| Return on equity | 12.7%▲ best | 4.5% |
| Growth | ||
|---|---|---|
| Revenue growth | 32.7%▲ best | 4.9% |
| Revenue growth, 3 years a year | 23.5%▲ best | 6.1% |
| Earnings per share growth | 1000.0%▲ best | -3.4% |
| Financial strength | ||
|---|---|---|
| Debt to equity | — | 0.2× |
| Cash | ||
|---|---|---|
| Free cash flow margin | — | 16.6% |
| Altman Z-score zone | distress | — |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Aug 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.